Lower back pain after iodine-131-6-β-iodomethyl-19-norcholesterol injection: a case report
DOI:
https://doi.org/10.30827/ars.v63i2.23505Keywords:
NP-59, adverse drug reaction, pharmacovigilanceAbstract
The [131I]Iodine-6-β-iodomethyl-19-norcholesterol ([131I]Norcholesterol; NP-59), is indicated in the diagnosis of the functional state of adrenal cortical tissue, in the detection of functional tissue in hyperadrenocorticalism as well as in primary aldosteronism. We present the case of a 54-year-old woman, referred for evaluation of suspected aldosteronism, and who immediately after intravenous administration of [131I]Norcholesterol suffered a strong adverse drug reaction, with dizziness, flushing, increased blood pressure, chest tightness, low back pain and erythematous rash up to 9 days after injection. Symptoms resolved satisfactorily after administration of antihistamines and corticosteroids. This reaction was suspected to be related to the administration of [131I]Norcholesterol caused by a type I allergic reaction.
Downloads
References
Hesslewood SR, Keeling DH. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med. 1997;24:1179–82. DOI: 10.1007/BF01254254
Silberstein EB, Ryan J. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med. 1996;37:185–92.
Kazerooni EA, Sisson JC, Shapiro B, Gross MD, Driedger A, Hurwitz GA, Mattar AG, Petry NA. Diagnostic accuracy and pitfalls of [iodine-131]6-beta-iodomethyl-19-norcholesterol (NP-59) imaging. J Nucl Med. 1990; 31: 526-534.
Ficha Técnica norcolesterol iodado (131I). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Centro de Información de Medicamentos (CIMA)
https://cima.aemps.es/cima/dochtml/ft/71492/FichaTecnica_71492.html (última visualización 30 de enero de 2022)
Maltby PJ, Smith ML. An adverse reaction to [131I]iodomethylnorcholesterol. Nucl Med Commun. 2002; 23:505–506. DOI: 10.1097/00006231-200205000-00014
Spyridonidis T, Giannakenas C, Lakiotis V, Apostolopoulos DJ. Adverse reactions following NP-59 administration. Nucl Med Commun. 2008;29(8):749–750. DOI: 10.1097/MNM.0b013e328301834c
Subcommittee of Safety Issue for the Radiopharmaceuticals, Medical and Pharmaceutical Committee, Japan Radioisotope Association. The twenty-second report on survey of the adverse reaction to radiopharmaceuticals (the 25th survey in 1999). Kaku Igaku. 2001; 38: 139-50.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Juan Antonio Pérez-Iruela
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
